Plausible effects of sodium-glucose cotransporter-2 inhibitors on adverse cardiac remodelling
Abstract
This editorial refers to ‘Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodeling: a systematic review and meta-analysis’, by N. Zhang et al. doi:10.1093/eurjpc/zwab173. Adverse cardiac remodelling (ACR) is a common characteristic of abnormalities of cardiac structure and functions, which are a result of natural evolution of numerous cardiovascular (CV) disease and other conditions, such as type 2 diabetes mellitus (T2DM).1 The pathogenesis of ACR is complex and closely relates to the occurrence of heart failure (HF).2,3 During the last decades, ACR has been considering a target for HF point-of-care, while the most dramatic benefits regarding a reversion of impaired cardiac structure and altered function appeared after implementation in routine clinical practice four-component optimal HF therapy including sodium-glucose cotransporter 2 (SGLT2) inhibitor.4 Although SGLT2 inhibitors sufficiently improved CV outcomes in patients with T2DM with or without HF, the exact molecular mechanisms by which they interfered in nature evolution of ACR and HF remains uncertain.5 Moreover, it has not clear, whether SGLT2 inhibitors improved HF-related outcomes through a reversion of ACR.6 The study by Zhang et al.7 published in this issue of the European Journal of Preventive Cardiology has provided a meta-analysis of 13 randomized clinical trials dedicated to an impact of four SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, and luseogliflozin) on ACR in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,251 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.